UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., Petitioner,

v.

BRISTOL-MYERS SQUIBB CO. and PFIZER INC.,

Patent Owners.

IPR No. 2018-00892 Patent No. 9,326,945 B2

DECLARATION OF AMY K. WIGMORE IN SUPPORT OF MOTION FOR ADMISSION PRO HAC VICE



IPR No. 2018-00892 Patent No. 9,326,945 B2

I, Amy K. Wigmore, declare as follows:

- I obtained a B.A. from the University of Massachusetts in 1992 and a
 J.D. from the Harvard Law School in 1995.
- 2. I am currently a partner in the law firm of Wilmer Cutler Hale and Dorr LLP. I was admitted to the Massachusetts Bar in January of 1996 and the District of Columbia Bar in December of 1996. I have been practicing law for over 20 years. For more than 11 years, my practice has focused primarily on patent litigation. Over the course of my career, I have been counsel in dozens of patent litigations.
- 3. I am a member in good standing of the Bars of the Commonwealth of Massachusetts and District of Columbia. I am admitted to practice before the U.S. District Courts for the District of Columbia, District of Colorado, and District of Massachusetts. I am also admitted to practice before the U.S. Court of Appeals for the Federal Circuit, the D.C. Circuit, and the Sixth Circuit, as well as the Supreme Court of the United States. I am also admitted to practice before the District of Columbia Court of Appeal and the Supreme Judicial Court of Massachusetts.
- 4. My Massachusetts Bar membership number is 629275. My District of Columbia Bar membership number is 453164.
- 5. In the past three years, I have appeared *pro hac vice* before the Office in the following proceedings: *Apotex Inc. v. OSI Pharmaceuticals Inc.*, IPR2016-



01284 (pro hac vice granted); OSI Pharmaceuticals, LLC v. Arch Development
Corp., IPR2016-01034 (pro hac vice granted); Boehringer Ingelheim GmbH v.
AbbVie Biotechnology Ltd., IPR2016-00408 (pro hac vice granted); Boehringer
Ingelheim GmbH v. AbbVie Biotechnology Ltd., IPR2016-00409 (pro hac vice
granted); Coherus BioSciences Inc. v. AbbVie Biotechnology Ltd., IPR2016-00188
(pro hac vice granted); Coherus BioSciences Inc. v. AbbVie Biotechnology Ltd.,
IPR2016-00189 (pro hac vice granted); Coherus BioSciences Inc. v. AbbVie
Biotechnology Ltd., IPR2016-00172 (pro hac vice granted).

- 6. I have an established familiarity with the subject matter of U.S. Patent No. 9,326,945 (the '945 patent), the '945 patent's file history, and the prior art at issue in this proceeding. I have been representing Bristol-Myers Squibb Co. and Pfizer Inc. in connection with matters concerning the '945 patent since 2015 and currently represent Bristol-Myers Squibb Co. and Pfizer Inc. in the related district court cases involving the '945 patent identified in Patent Owners' Mandatory Notices. I have also recently represented other pharmaceutical companies, including, among others, OSI Pharmaceuticals, Inc., AbbVie, Inc., GlaxoSmithKline plc, and Wyeth in intellectual property matters before federal district courts and appellate courts, including matters involving formulation technology.
 - 7. I have never been suspended or disbarred from practice before any



IPR No. 2018-00892 Patent No. 9,326,945 B2

court or administrative body.

- 8. I have never had a court or administrative body deny my application for admission to practice.
- 9. I have never had any sanctions or contempt citations imposed on me by any court or administrative body.
- 10. I have read and will comply with Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials, as set forth in 37 C.F.R. Part 42.
- 11. I agree to be subject to the United States Patent and Trademark Office Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq. and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like are punishable by fine, imprisonment, or both, under Section 1001 of Title 18 of the United States Code.



Respectfully submitted,

Dated: May 14, 2018

/Amy K. Wigmore/
Amy K. Wigmore
WILMER CUTLER PICKERING
HALE AND DORR LLP
1875 Pennsylvania Ave NW
Washington, DC, 20006
Amy.Wigmore@wilmerhale.com

Tel.: 202-663-6096 Fax: 202-663-6363

